Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Heron Therapeutics: Assessing The Prospects Of An Innovator Servicing The Pain And Cancer Markets

|About: Heron Therapeutics, Inc. (HRTX), Includes: NKTR
Summary

Heron is an interesting grower that has an enriched pipeline of both approved drugs and medicines in-development.

Company concurrently runs two market segments, cancer-induced nausea and vomiting (“CINV”) as well as pain control.

Two approved molecules for CINV are generating increasing revenues to power other innovation.

HTX-011 already passed its phase 3 trial with flying colors (and is most likely to gain an FDA approval).

Revenues should be ramping up within a year.

The iron rule of nature is: you get what you reward for. If you want ants to come, you put sugar on the floor. - Charlie Munger

Heron Therapeutics (NASDAQ:HRTX) is an intriguing company brought to our attention by a subscriber of Integrated BioSci Investing. One of our goals is to conduct analytical research to assist our members in their own due diligence process. That being said, Heron is powering an enriched pipeline, in which the binary risks are already substantially reduced. In the past 52-week, the stock exchanged hands $18.15 higher at $31.40 for over 136.9% profits. The elephant in the room is where the share price is heading. In this research, we’ll assess the underlying fundamentals (and upcoming catalysts) that dictate the forward market valuation of Heron.

Figure 1: Heron stock chart. (Source: StockCharts)

About The Company

Headquartered in San Diego CA, Heron focuses on the innovation and commercialization of therapeutics to service the pain as well as CINV markets. As shown in figure 2, there are two molecules for being launched for CINV: (1) Sustolis an extended release version of granisetron and (2) Cinvanti, an injectable emulsion of aprepitant, which has been available in the market for over a quarter. Cinvanti was FDA approved on Nov. 9, 2017, and marketed in the U.S. on Jan. 04, 2018. That aside, HTX-011 is being developed for two types of pain reduction - post-op in local administration and post-op pain in nerve block.

Figure 2: Therapeutic pipeline. (Source: Heron)

Final Remarks

This is a preview of the Integrated BioSci Research that was published in advanced and exclusively for subscribers of Integrated BioSci Investing. Of note, we periodically send out a completely FREE Integrated BioSci Research to people in Dr. Tran BioSci's mailing list. Be sure to sign up for our mailing list HERE to not miss a single article.

We Invite you to try our FREE 2-week trial (and, to lock in the current price to save money for the future).

Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 181% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 164% gains; Kite Pharma netted 83%; Atara Biotherapeutics (NASDAQ:ATRA) appreciated +202%. Crispr Therapeutics (NASDAQ:CRSP) garned plus 242%. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we’ll increase our price soon. SUBSCRIBE to our marketplace research now to lock in the current price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by followingthis link. If you'd like to get our other once weekly ideas sent to your mailbox, check out Dr. Tran BioSci and sign up with our mailing list.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: Our research articles are best used as starting points in your own due diligence. We are not registered investment advisors and our articles are not construed as professional investment advice. This research on HRTX was a request from a subscriber of our marketplace service to assist our members in their own research. That aside, I like to inform readers of Seeking Alpha's recent policy change, in which the company implemented the paywall (not only to our articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.